| Ytd | 24.60% | |
| 1y | 52.29% |
| Open | 2.35 | Prev Close | 2.30 | Low | 2.21 | High | 2.47 | Mkt Cap | 724.24M |
| Vol | 12.82M | Avg Vol | 10.39M | EPS | -0.44 | P/E | N/A | Forward P/E | -2.84 |
| Beta | 2.01 | Short Ratio | 4.46 | Inst. Own | 84.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.52 | 200-d Avg | 1.59 | 1yr Est | 3.02 |
PACB News
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider James Gibson II sol
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a
U.S. stocks rose; Apogee surged 10% on strong results and raised guidance, while Option Care, Ginkgo
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and TychoBio,
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug d
Pacific Biosciences of California (PACB) concluded the recent trading session at $2.54, signifying a
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of Californi
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and oth
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the recipient of unusua
Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday'
Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) rose 6.1% on Mond
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +
Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indica
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthc
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and low
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition rais
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi
Pacific Biosciences of California NASDAQ: PACB reported second-quarter revenue of $39 million, inclu
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to of
Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates and guiding 2026 reven
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuri
Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million
Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of hi
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the an
On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50
Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level predict
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and
Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
The protocol will be formally presented at the upcoming American Association for Cancer Research (AA
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to U
Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod
PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno
PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today ann
PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, ann
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and
